CR20140567A - Formulaciones y métodos para la administración vaginal de antiprogestinas - Google Patents

Formulaciones y métodos para la administración vaginal de antiprogestinas

Info

Publication number
CR20140567A
CR20140567A CR20140567A CR20140567A CR20140567A CR 20140567 A CR20140567 A CR 20140567A CR 20140567 A CR20140567 A CR 20140567A CR 20140567 A CR20140567 A CR 20140567A CR 20140567 A CR20140567 A CR 20140567A
Authority
CR
Costa Rica
Prior art keywords
vaginal administration
antiprogestines
formulations
methods
relevant
Prior art date
Application number
CR20140567A
Other languages
English (en)
Inventor
Joseph S Podolski
Kuang Hsu
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140567(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of CR20140567A publication Critical patent/CR20140567A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La materia objeto de la presente invención es pertinente al campo de la administración vaginal de agentes farmacéuticamente activos.
CR20140567A 2012-05-31 2014-12-09 Formulaciones y métodos para la administración vaginal de antiprogestinas CR20140567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653674P 2012-05-31 2012-05-31
PCT/US2013/043447 WO2013181449A1 (en) 2012-05-31 2013-05-30 Formulations and methods for vaginal delivery of antiprogestins

Publications (1)

Publication Number Publication Date
CR20140567A true CR20140567A (es) 2015-03-09

Family

ID=48614182

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140567A CR20140567A (es) 2012-05-31 2014-12-09 Formulaciones y métodos para la administración vaginal de antiprogestinas

Country Status (23)

Country Link
US (1) US10328022B2 (es)
EP (1) EP2854763B1 (es)
JP (1) JP6341910B2 (es)
KR (1) KR102127348B1 (es)
CN (1) CN104334158B (es)
AU (1) AU2013267359C1 (es)
BR (1) BR112014029131B1 (es)
CA (1) CA2872644A1 (es)
CL (1) CL2014003232A1 (es)
CO (1) CO7141411A2 (es)
CR (1) CR20140567A (es)
EA (1) EA030444B1 (es)
ES (1) ES2701400T3 (es)
HK (1) HK1206622A1 (es)
IL (1) IL235450B (es)
IN (1) IN2014DN10548A (es)
MX (2) MX363640B (es)
NZ (1) NZ702467A (es)
PH (1) PH12014502516A1 (es)
SG (2) SG11201407397WA (es)
UA (1) UA114106C2 (es)
WO (1) WO2013181449A1 (es)
ZA (1) ZA201408262B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然複合ホルモン補充製剤および療法
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP6591447B2 (ja) * 2014-05-05 2019-10-16 レプロス セラピューティクス インコーポレイティド 抗プロゲスチンの膣内送達用の製剤と方法
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
CA2964628A1 (en) * 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3025709B1 (en) 2014-11-27 2020-09-30 Capsugel Belgium NV Dosage form articles for external mucosal applications
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112019021396A2 (pt) 2017-04-14 2020-04-28 Capsugel Belgium Nv processo para fabricação de pululano
CN110678170A (zh) * 2017-04-14 2020-01-10 比利时胶囊公司 普鲁兰多糖胶囊

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
DE3237814A1 (de) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
WO1985002092A1 (en) 1983-11-14 1985-05-23 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP0806952B1 (de) 1995-02-02 2003-04-02 Schering Aktiengesellschaft Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
GB9522403D0 (en) * 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
HU230492B1 (hu) 1996-05-01 2016-08-29 The Government Of The United States Of America Új progesztációt gátló szerként használható 21-helyzetben szubsztituált progeszteron-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk
AU2805397A (en) 1996-08-30 1998-03-19 Population Council, Center For Biomedical Research, The Vaginal application mifepristone
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US20050070516A1 (en) 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
EP1265911B1 (en) * 2000-03-17 2008-05-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
IN191020B (es) 2000-03-28 2003-09-13 Dabur Res Foundation
ATE310522T1 (de) 2000-10-18 2005-12-15 Schering Ag Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
CA2777199A1 (en) 2001-07-09 2003-01-23 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
WO2003020210A2 (en) 2001-08-29 2003-03-13 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
JP2003143474A (ja) 2001-11-02 2003-05-16 Matsushita Electric Ind Co Ltd 映像信号処理システム
US7417013B2 (en) 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
AU2004233997C1 (en) 2003-04-29 2014-01-30 Massachusetts Institiute Of Technology Methods and devices for the sustained release of multiple drugs
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
KR101229701B1 (ko) 2004-07-09 2013-02-05 라보라토이레 에이치알에이 파르마 프로게스테론 수용체 조절제를 함유하는 서방형 조성물
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
EP2392322A3 (en) 2005-03-22 2012-02-22 Repros Therapeutics Inc. Dosing regimes for trans-clomiphene
EP1874732A1 (en) 2005-04-20 2008-01-09 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
DE102005030294A1 (de) 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
JP2009510127A (ja) * 2005-09-29 2009-03-12 リプロス セラピューティクス インコーポレイテッド ステロイド誘導体および多糖分解されたグリセリドを含む、向上したバイオアベイラビリティーを伴う処方物
CN1846703A (zh) 2006-02-13 2006-10-18 程定超 米非司酮阴道给药制剂及其组成和制备方法
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
JP2008012281A (ja) * 2006-06-05 2008-01-24 Koritsu Shoji:Kk 挿入補助器具
KR20070116538A (ko) * 2006-06-05 2007-12-10 유겐가이샤 코리츠 쇼지 삽입 보조 기구
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CA2673128C (en) 2006-10-24 2018-07-03 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
JP5379121B2 (ja) * 2007-04-05 2013-12-25 ユニバーシティ・オブ・カンザス プルランを含む速溶性医薬組成物
PL2148681T3 (pl) 2007-04-20 2016-09-30 Selektywny modulator progesteronu w leczeniu krwawienia z macicy
WO2009037704A1 (en) * 2007-09-20 2009-03-26 Bio-Pro Medical Ltd. Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endrometriosis, adenomyosis and related disorders by mifepristone
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
WO2011039680A1 (en) * 2009-09-29 2011-04-07 Koninklijke Philips Electronics N.V. Intrauterine electronic capsule for administering a substance
UA113283C2 (xx) 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
WO2012121767A1 (en) 2011-03-09 2012-09-13 Arstat, Inc. Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування

Also Published As

Publication number Publication date
JP2015518052A (ja) 2015-06-25
PH12014502516B1 (en) 2015-01-12
IL235450A0 (en) 2014-12-31
BR112014029131B1 (pt) 2021-03-09
HK1206622A1 (en) 2016-01-15
KR20150014928A (ko) 2015-02-09
EP2854763B1 (en) 2018-09-26
KR102127348B1 (ko) 2020-06-29
NZ702467A (en) 2016-07-29
AU2013267359B2 (en) 2016-05-26
SG10201704858PA (en) 2017-07-28
AU2013267359A1 (en) 2014-11-20
CN104334158B (zh) 2018-08-10
CO7141411A2 (es) 2014-12-12
CN104334158A (zh) 2015-02-04
IL235450B (en) 2020-02-27
UA114106C2 (xx) 2017-04-25
SG11201407397WA (en) 2014-12-30
IN2014DN10548A (es) 2015-08-21
EA201492290A1 (ru) 2015-03-31
WO2013181449A1 (en) 2013-12-05
EP2854763A1 (en) 2015-04-08
AU2013267359C1 (en) 2016-09-29
MX363640B (es) 2019-03-28
MX2014014054A (es) 2015-02-12
CA2872644A1 (en) 2013-12-05
CL2014003232A1 (es) 2015-03-13
ES2701400T3 (es) 2019-02-22
EA030444B1 (ru) 2018-08-31
PH12014502516A1 (en) 2015-01-12
US20150111862A1 (en) 2015-04-23
BR112014029131A2 (pt) 2018-05-29
JP6341910B2 (ja) 2018-06-13
US10328022B2 (en) 2019-06-25
ZA201408262B (en) 2015-12-23
MX2019003467A (es) 2019-06-06

Similar Documents

Publication Publication Date Title
CR20140567A (es) Formulaciones y métodos para la administración vaginal de antiprogestinas
PH12019500176A1 (en) Heterocyclic compounds and ther uses
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
BR112014030165A2 (pt) inibidores do bromodomínio de benzo [c] isoxazoloazepina e seu uso
GT201400196A (es) Compuestos de heterociclilo
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201491486A1 (ru) Производные пиперидинопиримидина для лечения вирусных инфекций
MX2015017964A (es) Inhibidores de bromodominio.
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
CR20140513A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
MX2015012416A (es) Compuestos heterociclicos y sus usos.
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
MX2015017202A (es) Formulacion de liberacion modificada.
UY34829A (es) Nueva dosificación y formulación
BR112015027436A2 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
CR20130488A (es) Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
DOP2013000284A (es) Derivados de pirazol útiles como inhibidores de aldosterona sintasa
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции